GO:0071133 alpha9-beta1 integrin-ADAM8 complex

The alpha9-beta1 integrin-ADAM8 complex (GO:0071133) is a specific cell-surface protein assembly in which the alpha9-beta1 integrin heterodimer is bound to the transmembrane metallopeptidase ADAM8. This complex is a cellular_component in the Gene Ontology, meaning it represents a physical entity rather than a biological process or a molecular function. Understanding this complex is important because it sits at the intersection of cell adhesion and proteolysis, two processes that control tissue remodeling, stem cell behavior, and immune responses. The alpha9-beta1 integrin heterodimer is composed of ITGA9 and ITGB1, and its association with ADAM8 brings a catalytic metallopeptidase into proximity with adhesion receptors. This arrangement allows the complex to both anchor cells to the extracellular matrix and to cleave specific substrates, thereby influencing signaling and cell fate. Researchers study GO:0071133 to dissect how adhesion-coupled proteolysis contributes to normal physiology and to diseases such as cancer and inflammatory conditions. Because the complex is membrane-associated, its assembly and activity are highly dependent on the cellular context, including the presence of specific ligands and the activation state of the integrin. The QuickGO definition provides a precise anchor for annotation, but experimental work is needed to determine when and where this complex forms in vivo. This article reviews the components, assembly, regulation, and research methods relevant to GO:0071133, with a focus on how CRISPR-based models can be used to probe its function.

GO:0071133, alpha9-beta1 integrin-ADAM8 complex, is defined as a protein complex that consists of an alpha9-beta1 integrin complex bound to the transmembrane metallopeptidase ADAM8. In other words, it is a heteromeric assembly in which the integrin heterodimer (ITGA9/ITGB1) physically associates with ADAM8 at the cell membrane. This term belongs to the cellular_component ontology, indicating that it describes a stable molecular structure rather than a dynamic process or an isolated enzymatic activity. The synonym ITGA9-ITGB1-ADAM8 complex reflects the gene symbols of the three core subunits. Because the definition is based on physical binding, the complex is expected to be detectable by co-immunoprecipitation, proximity labeling, or single-molecule imaging when the subunits are co-expressed. The definition does not specify stoichiometry or whether additional proteins are present, so the core complex is best regarded as a minimal functional unit.

The alpha9-beta1 integrin-ADAM8 complex is important because it links two fundamental cellular activities: adhesion to the extracellular matrix and proteolytic cleavage of membrane proteins. This coupling allows cells to sense their environment and simultaneously modify it, a capability that is critical for tissue development, wound healing, and immune cell trafficking. In the hematopoietic system, factors released by megakaryocytes can thrombin-cleave osteopontin to negatively regulate hematopoietic stem cells, and integrin-ADAM8 complexes may influence this niche signaling. Because ADAM8 is a metallopeptidase, its association with alpha9-beta1 integrin could localize proteolytic activity to specific adhesion sites, thereby controlling the release of growth factors and cytokines. Dysregulation of this complex has been proposed to contribute to cancer progression, chronic inflammation, and stem cell exhaustion. Therefore, studying GO:0071133 provides mechanistic insight into how adhesion-dependent proteolysis shapes cell behavior in health and disease.

The following genes and proteins are the core components and key regulators of the alpha9-beta1 integrin-ADAM8 complex (GO:0071133) and its associated biology.

The assembly and activity of the alpha9-beta1 integrin-ADAM8 complex are regulated at multiple levels. Integrin activation, which involves conformational changes and inside-out signaling, can control whether the heterodimer is competent to bind ADAM8. The proteolytic activity of ADAM8 is regulated by its prodomain removal, zinc availability, and endogenous inhibitors such as TIMPs. In hematopoietic stem cells, thrombin-cleaved osteopontin generated by megakaryocyte-derived factors negatively regulates stem cell function, and this pathway may intersect with integrin-ADAM8 complexes. Cytokines and growth factors in the niche can modulate the expression of ITGA9, ITGB1, and ADAM8, thereby influencing complex abundance. Post-translational modifications and membrane trafficking also contribute to the spatiotemporal regulation of the complex. Because the complex sits at the interface of adhesion and proteolysis, its regulation is likely to be highly context-dependent and cell-type specific.

The alpha9-beta1 integrin-ADAM8 complex may influence hematopoietic stem cell (HSC) behavior through its interaction with osteopontin, a key niche factor. Megakaryocytes release factors that thrombin-cleave osteopontin, generating a fragment that negatively regulates HSCs. If the complex modulates osteopontin cleavage or adhesion to osteopontin, its dysregulation could contribute to HSC exhaustion or bone marrow failure. Experimental models using knockout mice or CRISPR-edited human HSCs could test this hypothesis.

ADAM8 is overexpressed in several cancers, including lung, pancreatic, and breast cancer, and is associated with poor prognosis. Its association with alpha9-beta1 integrin in the complex could localize proteolytic activity to tumor-stroma interfaces, promoting invasion and metastasis. The integrin heterodimer itself is implicated in cancer cell adhesion to extracellular matrix components such as osteopontin and tenascin-C. Targeting the complex with blocking antibodies or small-molecule inhibitors may reduce tumor progression. CRISPR knockout of ADAM8 or ITGA9 in cancer cell lines can be used to test these ideas.

The alpha9-beta1 integrin is involved in leukocyte trafficking and inflammation, and ADAM8 is expressed in neutrophils and other immune cells. The complex may facilitate the shedding of adhesion molecules or cytokines that amplify inflammatory responses. Dysregulated complex activity could contribute to chronic inflammatory conditions such as rheumatoid arthritis or inflammatory bowel disease. Experimental models using conditional knockout mice or human immune cells edited with CRISPR can help define the complex's role in inflammation.

Alpha9-beta1 integrin is known to regulate lymphangiogenesis, the formation of new lymphatic vessels. ADAM8 may modulate this process by cleaving extracellular matrix or growth factors. The complex could therefore influence tissue remodeling in development and disease. Knockout and knock-in models in endothelial or lymphatic cells can be used to study this biology.

Co-immunoprecipitation (co-IP) is a classic method to detect the alpha9-beta1 integrin-ADAM8 complex. Cells are lysed under mild conditions, and antibodies against one subunit (e.g., ADAM8) are used to pull down the complex, followed by immunoblotting for the other subunits. Affinity purification coupled with mass spectrometry can identify additional interacting proteins and post-translational modifications. These methods require careful controls to distinguish specific interactions from nonspecific binding.

Proximity labeling techniques such as BioID or APEX can detect proteins in close proximity to a bait subunit in living cells. By tagging ADAM8 or ITGA9 with a proximity label, researchers can map the interactome of the complex in its native environment. Fluorescence microscopy, including FRET and super-resolution imaging, can visualize the co-localization and dynamics of the subunits at the plasma membrane. These approaches are valuable for confirming complex formation in situ.

The metallopeptidase activity of ADAM8 within the complex can be measured using fluorogenic peptide substrates or by monitoring cleavage of physiological substrates such as osteopontin. Activity assays can be performed on live cells, membrane fractions, or purified recombinant proteins. Inhibitors such as TIMPs or small molecules can be used to confirm specificity. These assays help determine whether complex formation modulates ADAM8 catalytic activity.

CRISPR knockout libraries can be used to identify genes required for alpha9-beta1 integrin-ADAM8 complex assembly or function. For example, a reporter cell line that expresses a fluorescent complex component can be subjected to genome-wide knockout screening to find regulators. Similarly, CRISPR activation or interference screens can identify genes that enhance or suppress complex formation. These approaches provide unbiased insights into the genetic network controlling the complex.

Researchers studying alpha9-beta1 integrin-ADAM8 complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, adhesion, or proteolysis. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models that answer these questions.

The alpha9-beta1 integrin-ADAM8 complex (GO:0071133) is a specialized cell-surface assembly that couples adhesion to proteolysis. Its core components ITGA9, ITGB1, and ADAM8 are implicated in diverse biological processes, from hematopoietic stem cell regulation to cancer progression. Understanding how this complex assembles and functions requires precise genetic models, and CRISPR-based approaches are uniquely suited to dissect its roles. Future research using knockout, point mutation, knock-in, and overexpression models will likely reveal new therapeutic opportunities targeting this complex.